Kosh Agarwal - Dissemin

Papers authored by Kosh Agarwal

This paper was not found in any repository, but could be made available legally by the author.

2016 M. C. M. Cheung, G. R. Foster, W. L. Irving, A. J. Walker, B. E. Hudson, S. Verma, J. McLauchlan, D. J. Mutimer, A. Brown, W. Gelson, D. MacDonald, K. Agarwal

Antiviral Treatment in Patients with Advanced Hcv Cirrhosis Using Sofosbuvir and Ledipasvir/Daclatasvir with or without Ribavirin - 6 and 12 Month Outcomes Compared to Untreated Patients

Upload

J. S. Nayagam, O. Raja, K. Agarwal

, N. Heaton, M. Heneghan, J. O’Grady, A. Suddle, V. Aluvihare

Patients who Underwent Percutaneous Coronary Intervention Prior to Liver Transplantation Did Not Experience Bleeding Complications Whilst on Dual Antiplatelet Therapy

Upload

J. S. Nayagam, K. Abeysekera, K. Agarwal

, N. Heaton, M. Heneghan, J. O’Grady, A. Suddle, V. Aluvihare

Outpatient Liver Transplantation Assessment is an Effective Tool with No Evidence of Delay in Decision Making

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

S. Strasser, S. Roberts, P. Angus, H. L. Y. Chan, S. Fung, W. K. Seto, W. L. Chuang, C. Y. Chen, H. J. Kim, A. J. Hui, H. L. A. Janssen, A. Chowdhury, T. Y. O. Tsang, R. Mehta, E. Gane and 9 other authors

A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety results

Upload

D. Iser, E. J. Lawitz, P. Ruane, C. Stedman, G. Foster, H. M. Mir, R. H. Hyland, S. Coogan, S. Moody, H. Dvory-Sobol, S. J. Knox, D. M. Brainard, A. Abergel, K. Agarwal

, Z. Younes and 1 other authors

Long-Term Follow-Up of Patients with Chronic HCV Infection following Treatment with Direct Acting Antiviral Regimens: Maintenance of SVR, Persistence of Resistance Mutations and Clinical Outcomes

Upload

Ivana Carey, Kate Childs, Dazhuang Shang, Sarah Hughes, Matthew Bruce, Mary Horner, Bo Wang, David Gong, Anuj Gaggar, Kosh Agarwal

HBsAg production in HBV/HDV patients impacts on maturation of NK cells and is pro-apoptotic to T cells via TRAIL-TRAIL-R2 interaction: a mechanism of persistence?

Upload

Suman Verma, Suman Verma, Graham R. Foster, Graham R. Foster, Matthew D. Sadler, Matthew D. Sadler, Michael A. Heneghan, Michael A. Heneghan, William Irving, William Irving, Aisling B. Considine, Aisling B. Considine, Kate Childs, Kate Childs, Abid Suddle and 5 other authors

Decreased health resource utilization by peri-transplant (PT) HCV patients after successful direct acting antiviral (DAA) therapy

Upload

Matthew D. Sadler, Enoka Gonsalkorala, Matthew J. Bruce, Mary Horner, Kosh Agarwal

, Ivana Carey

Quantitative Hepatitis B Surface Antigen Does Not Reliably Identify Patients with Active Hepatitis D Virus Infection

Upload

Gayatri Chakrabarty, Ivana Carey, Kosh Agarwal

, Daniel M. Forton

Non-invasive prediction of liver disease in a multi-genotype cohort of hepatitis B e antigen negative patients

Upload

Kosh Agarwal

, Kosh Agarwal, Norihiro Furusyo, Norihiro Furusyo, Kwan Soo Byun, Kwan Soo Byun, Jaeseok Hwang, Jaeseok Hwang, John F. Flaherty, John F. Flaherty, Kyungpil Kim, Kyungpil Kim, Anuj Gaggar, Anuj Gaggar, Mani Subramanian and 9 other authors

Improved Renal Laboratory Parameters In CHB Patients Treated With TAF Compared With Tenofovir Disoproxil Fumarate (TDF)

Upload

Stephen Shafran, David Shaw, Mariem Charafeddine, Kosh Agarwal

, Graham R. Foster, Manal Abunimeh, Bo Fu, Tami Pilot-Matias, Rajvineeth K. Pothacamury, Eric Cohen, Daniel E. Cohen, Edward J. Gane

QUARTZ II-III: Final Efficacy and Safety Results in Patients with HCV Genotype 2 or 3 Infection Treated With Ombitasvir/Paritaprevir/Ritonavir and Sofosbuvir With or Without Ribavirin

Upload

E. J. Gane, S. Pianko, S. K. Roberts, A. J. Thompson, S. Zeuzem, E. Zuckerman, Z. B. Ari, G. R. Foster, K. Agarwal

, A. L. Laursen, J. Gerstoft, W. Gao, H.-C. Huang, B. Fitzgerald, J. J. Li and 7 other authors

High Efficacy of an 8-Week 3-Drug Regimen of Grazoprevir/MK-8408/MK-3682 in HCV Genotype 1, 2 and 3-Infected Patients: SVR24 Data from the Phase 2 C-Crest 1 and 2 Studies

Upload

F. AgÃ¼ero, L. A. Barcan, F. SuÃ¡rez, P. Vazquez, E. de Lazzari, A. Rimola, F. Torres, P. Stock, C. Tural, M. Tuset, J. M. MirÃ³, E. Varo, P. Grossi, Pedreira, Castro and 240 other authors

Liver Retransplantation in Patients With HIV-1 Infection: An International Multicenter Cohort Study

Upload

Kosh Agarwal

, Emily O. Dumas, Giovanni B. Gaeta, Sam Lee, Adrian Streinu-Cercel, Eckart Schott, Raul J. Andrade, Alma M. Perez, Jacob George, Igor G. Bakulin, Rui T. Marinho, Resat Ozaras, Mariem Charafeddine, Li Liu, Tami Pilot-Matias and 4 other authors

Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I

Upload

Xavier Forns, Didier Samuel, David Mutimer, Stefano Fagiuoli, Miguel Navasa, Kosh Agarwal

, Marina Berenguer, Massimo Colombo, Kerstin Herzer, Frederik Nevens, Bjorn Daems, Katrien Janssen, Sivi Ouwerkerk-Mahadevan, Holly Kimko, Erkki Lathouwers and 2 other authors

Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C

Upload

K. Macdonald, K. Childs, A. Quaglia, K. Agarwal

, A. Suddle, C. Taylor

Autoimmune hepatitis (AIH) in HIV infection: an emerging cause of significant liver disease in patients on combination antiretroviral therapy (cART)?

Upload

K. Childs, A. Suddle, K. Agarwal

, C. Taylor, K. MacDonald

The burden of non-viral liver disease in patients referred to an HIV/liver clinic: the tip of the iceberg?

Upload

Kosh Agarwal

, Michael Schultz, Stephen Pianko, Leslie Bank, Jane Collier, Jacob George, Matthew Priest, Stephen D. Ryder, Blaire E. Burman, Kuldeep Cheent, Matthew Cramp, Daniel M. Forton, Barbara A. Leggett, Gerry C. MacQuillan, Alnoor Ramji and 13 other authors

Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin

Upload

Graham R. Foster, Alex J. Thompson, Peter J. Ruane, Sergio M. Borgia, Gregory Dore, Kimberly Workowski, Robert H. Hyland, Jing Wang, Evguenia S. Svarovskaia, Luisa M. Stamm, Diana M. Brainard, Mani Subramanian, John G. McHutchison, Thomas Berg, Kosh Agarwal

and 4 other authors

A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study

Upload

Edward J. Gane, Ricard Sola, Eric Cohen, Stuart K. Roberts, Jacob George, Richard Skoien, Stephen Riordan, Niloufar Mobashery, Manal Abunimeh, Daniel E. Cohen, Kosh Agarwal

RUBY-II: Efficacy and Safety of a Ribavirin-free Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir Regimen in Patients with Severe Renal Impairment or End-Stage Renal Disease and HCV Genotypes 1a or 4 Infection

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

Papers authored by Kosh Agarwal